Asklepios BioPharmaceutical (AskBio), a gene therapy subsidiary of Bayer, has presented first-in-human data from a Phase I trial investigating AB-1002 (also known as NAN-101) for the treatment of patients with congestive heart failure (CHF). The data were shared at the American Heart Association Scientific Sessions, which were held in Philadelphia, US, 11-13 November 2023. The […]
